Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Development Officer | August 21, 2023 | August 23, 2023 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date August 21, 2023 · Filed August 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,962 |
Reported balance
After 2023-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-21 · Sale · Disposed 1,490 · Balance 26,962 F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022.
F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares.
Vistagen Therapeutics, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09 | Direct | 17,600 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600 F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2025 Filed Sep 11, 2025 22:14 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,600 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001411685-25-000075 · edgardoc.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-09-09 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 21:00 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001415889-24-023147 · form4-09102024_050907.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2034-09-06 F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance ("Grant Date"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:00 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-24-007096 · form4-03062024_060307.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-04 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 21:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,490 | $16.66 | $24,817.14 |
DisclosureSEC source: 0001209191-23-047103 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,962 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-23-010542 · doc4.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Class A Common Stock · 150,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:01 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 2,212 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-061973 · doc4.xml · derivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,801 Underlying: Class A Common Stock · 2,212 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:01 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 783 | $20.17 | $15,792.88 |
DisclosureSEC source: 0001209191-22-061973 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.06 to $20.515, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:01 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 783 | $2.90 | $2,268.19 |
DisclosureSEC source: 0001209191-22-061973 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:01 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,429 | $19.12 | $27,323.05 |
DisclosureSEC source: 0001209191-22-061973 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.88 to $19.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:01 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,429 | $2.90 | $4,139.53 |
DisclosureSEC source: 0001209191-22-061973 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 1,078 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · derivative · entry 9 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,639 Underlying: Class A Common Stock · 1,078 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 11,733 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · derivative · entry 8 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,384 Underlying: Class A Common Stock · 11,733 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,078 | $18.19 | $19,608.82 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,078 | $6.37 | $6,869.88 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 11,733 | $18.28 | $214,440.52 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.09 to $18.92, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 11,733 | $11.00 | $129,063.00 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 6,900 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · derivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,117 Underlying: Class A Common Stock · 6,900 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,900 | $18.25 | $125,923.62 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.41, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,900 | $11.00 | $75,900.00 |
DisclosureSEC source: 0001209191-22-061178 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 494 | $16.47 | $8,136.18 |
DisclosureSEC source: 0001209191-22-060331 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,821 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 2,211 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · derivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,013 Underlying: Class A Common Stock · 2,211 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,078 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · derivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,717 Underlying: Class A Common Stock · 1,078 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,211 | $15.84 | $35,030.20 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.57 to $16.08, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,211 | $2.90 | $6,404.82 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,078 | $15.86 | $17,097.73 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.45 to $16.13, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,078 | $6.37 | $6,869.88 |
DisclosureSEC source: 0001209191-22-058095 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 494 | $16.54 | $8,170.76 |
DisclosureSEC source: 0001209191-22-056364 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,315 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 5,300 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · derivative · entry 11 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,017 Underlying: Class A Common Stock · 5,300 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 2,212 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · derivative · entry 10 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,224 Underlying: Class A Common Stock · 2,212 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,078 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · derivative · entry 9 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,795 Underlying: Class A Common Stock · 1,078 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2 | $20.30 | $40.60 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 8 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2 | $11.00 | $22.00 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,298 | $19.42 | $102,865.44 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.93, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,298 | $11.00 | $58,278.00 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,212 | $19.39 | $42,882.94 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.04 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,212 | $2.90 | $6,407.72 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,078 | $19.43 | $20,945.97 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.07 to $19.89, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 20:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,078 | $6.37 | $6,869.88 |
DisclosureSEC source: 0001209191-22-054192 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 988 | $21.64 | $21,380.32 |
DisclosureSEC source: 0001209191-22-052972 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,809 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 1,174 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · derivative · entry 20 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,317 Underlying: Class A Common Stock · 1,174 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 264 | $22.35 | $5,899.48 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 16 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.09 to $22.62, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 264 | $11.00 | $2,904.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 15 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 910 | $21.13 | $19,224.21 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 14 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.74 to $21.58, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 910 | $11.00 | $10,010.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 13 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 12,426 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · derivative · entry 19 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,491 Underlying: Class A Common Stock · 12,426 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 2,162 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · derivative · entry 18 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,436 Underlying: Class A Common Stock · 2,162 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,078 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · derivative · entry 17 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,873 Underlying: Class A Common Stock · 1,078 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,112 | $20.80 | $210,375.10 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 12 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.06, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,112 | $11.00 | $111,232.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 11 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,314 | $20.24 | $46,837.67 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 10 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.68 to $20.58, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.